Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Induction Therapy for Relapsed Childhood ALL
NCT00049569Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2003
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Feasibility of Intensified Sequential Induction Regimen at 4 months and Toxicity Assessment at 4 months. Started Jan 2003; status: completed.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00049569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049569.